New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT07275073
Summary
This is the first human study of an experimental drug called JMT106 for people with advanced solid tumors, including certain lung and liver cancers. The main goal is to find a safe dose and see how the body handles the drug in about 200 participants who have run out of standard treatment options. Researchers will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affilicated Hospital,Zhejiang University School of Medicine
RECRUITINGZhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.